Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (TSE:DTC)
:DTC
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.52 - C$1.50
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$33.93M
Enterprise ValueC$36.22M
Total Cash (Recent Filing)C$947.35K
Total Debt (Recent Filing)C$1.49M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding54,725,370
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Accum PlatformThe Accum™ delivery platform is a durable competitive asset: it targets intracellular delivery and immune potentiation across ADCs, vaccines and biologics. Platform applicability can produce multiple programs from the same tech base, spreading R&D risk and enabling longer-term partnership or licensing opportunities.
Platform Validation & Governance StepsPreclinical platform validation and creation of a Scientific Advisory Board strengthen scientific credibility and oversight, while converting convertible debentures to equity reduces near-term liability. Together these structural actions support continued R&D progress and improve governance and capital structure durability.
Reduced Operating LossesA marked reduction in net losses signals meaningful moderation in operating intensity and cost base. Sustained lower loss levels, if continued, extend runway, reduce immediate financing pressure, and suggest management is executing on expense discipline while advancing preclinical programs over the coming months.
Bears Say
No RevenueAbsence of commercial revenues means the business remains entirely R&D-stage and dependent on external capital. Without product sales or partnering receipts, funding needs are structural, increasing dilution risk and tying corporate viability to clinical and platform milestones rather than self-sustaining cash generation.
Negative Shareholders' Equity & Rising DebtNegative equity and a meaningful rise in reported debt materially weaken financial flexibility and can raise refinancing costs or restrictive covenants. This capital-structure strain elevates the risk that future financings are more dilutive or expensive, constraining strategic options over the medium term.
Persistent Negative Operating Cash FlowOngoing negative operating cash flow is a structural funding weakness for an early-stage biotech. Even with improvement, sustained cash burn requires serial financing rounds, which can dilute shareholders, delay programs if funding gaps occur, and limit the firm's ability to scale operations or pursue opportunistic partnerships.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.52 and its highest was C$1.50 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$33.93M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 88 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -C$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.028.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 54,725,370 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―